Advertisement

December 2, 2022

Erratum to ‘Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner’ [J Hepatol 77 (2022) 1059-1070]

  • June-Young Koh,
  • Min-Seok Rha,
  • Seong Jin Choi,
  • ...
  • Su-Hyung Park,
  • Dong Jin Joo,
  • Eui-Cheol Shin
Published online: December 02, 2022

December 1, 2022

Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss

  • Terry Cheuk-Fung Yip,
  • Vincent Wai-Sun Wong,
  • Mandy Sze-Man Lai,
  • ...
  • Yee-Kit Tse,
  • Henry Lik-Yuen Chan,
  • Grace Lai-Hung Wong
Published online: December 01, 2022

Corrigendum to ‘EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170–1218]

  • European Association for the Study of the Liver
  • Clinical Practice Guidelines Panel,
  • Chair,
  • EASL Governing Board Representative,
  • Panel Members
Published online: December 01, 2022

November 30, 2022

Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma

  • Jiaqi Sun,
  • Jun Ding,
  • Qingsong Shen,
  • ...
  • Hongliang Li,
  • Peng Zhang,
  • Zan Huang
Published online: November 30, 2022

November 29, 2022

Hyperhomocysteinemia predicts liver-related clinical outcomes in the general population

  • Fredrik Åberg,
  • Antti Jula,
  • Annamari Lundqvist,
  • Ville Männistö
Published online: November 29, 2022

Drug-induced liver injury due to nitrofurantoin: similar clinical features, but different HLA risk alleles in an independent cohort

  • Ann K. Daly,
  • Einar S. Bjornsson,
  • M. Isabel Lucena,
  • Raul J. Andrade,
  • Guruprasad P. Aithal
Published online: November 29, 2022

November 28, 2022

Reply to: Bepirovirsen / GSK3389404: antisense or TLR9 agonists?

  • Shihyun You,
  • Robert Elston,
  • Man-Fung Yuen
Published online: November 28, 2022

Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses

  • Vincent Wai-Hin Yuen,
  • David Kung-Chun Chiu,
  • Cheuk-Ting Law,
  • ...
  • Rex K.H. Au-Yeung,
  • Chun-Ming Wong,
  • Carmen Chak-Lui Wong
Published online: November 28, 2022

November 24, 2022

November 22, 2022

Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir

  • Rob W. van der Pluijm,
  • Loek P. Smits,
  • Sjoerd P. Rebers,
  • Janke Schinkel,
  • Marc van der Valk
Published online: November 22, 2022

November 21, 2022

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

  • Pierre Nahon,
  • Jessica Bamba-Funck,
  • Richard Layese,
  • ...
  • for the ANRS CO12 CirVir and CIRRAL groups.ANRS CO12 CirVir group,
  • CIRRAL group,
  • Centre de Ressources Biologiques (BB-0033-00027) Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny
Published online: November 21, 2022

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

  • Alexandre Louvet,
  • Valérie Bourcier,
  • Isabelle Archambeaud,
  • ...
  • Sylvie Chevret,
  • Nathalie Ganne-Carrié
  • for CIRRAL group
Published online: November 21, 2022

November 18, 2022

Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis

  • Christina Villard,
  • Ingalill Friis-Liby,
  • Fredrik Rorsman,
  • ...
  • Therese Hagström,
  • Emma Nilsson,
  • Annika Bergquist
Published online: November 18, 2022
Open Access

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

  • Veeral Ajmera,
  • Sandra Cepin,
  • Kaleb Tesfai,
  • ...
  • Cynthia Behling,
  • Claude B. Sirlin,
  • Rohit Loomba
Published online: November 18, 2022

November 16, 2022

Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease

  • George Cholankeril,
  • Jennifer R. Kramer,
  • Jinna Chu,
  • ...
  • Liang Li,
  • Hashem El-Serag,
  • Fasiha Kanwal
Published online: November 16, 2022

Biejia-Ruangan compound and incidence of hepatocellular carcinoma

  • Lei Luo,
  • Xuebing Yao,
  • Wenlong Yang
Published online: November 16, 2022

The concept of MAFLD gathers patients with distinct disease progression trajectories.

  • Pierre Deltenre,
  • Eric Trépo,
  • Christophe Moreno
Published online: November 16, 2022

November 15, 2022

Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS

  • Se Jin Choi,
  • Sang Hyun Choi,
  • Dong Wook Kim,
  • ...
  • Jae Ho Byun,
  • Hyung Jin Won,
  • Yong Moon Shin
Published online: November 15, 2022

November 14, 2022

Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma

  • Joachim Merters,
  • Angela Lamarca
Published online: November 14, 2022

November 11, 2022

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

  • Arun J. Sanyal,
  • Julie Foucquier,
  • Zobair M. Younossi,
  • ...
  • Véronique Miette,
  • Laurent Sandrin,
  • Jérôme Boursier
Published online: November 11, 2022
Open Access

November 9, 2022

Normothermic liver machine perfusion as a dynamic platform for assessment and treatment of organs from septic donors

  • Felix J. Krendl,
  • Rupert Oberhuber,
  • Robert Breitkopf,
  • Günter Weiss,
  • Stefan Schneeberger
Published online: November 09, 2022

MEFIB vs MAST and FAST: Not a competition but useful tools

  • Mazen Noureddin,
  • Stephen A. Harrison,
  • Naim Alkhouri
Published online: November 09, 2022

Prediction of liver-related mortality in a community setting

  • Carolin V. Schneider,
  • Stefan Gross,
  • Pavel Strnad
Published online: November 09, 2022

November 8, 2022

Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure

  • Francesca M. Trovato,
  • Rabiya Zia,
  • Florent Artru,
  • ...
  • Stephen R. Atkinson,
  • Evangelos Triantafyllou,
  • Mark JW. McPhail
Published online: November 08, 2022
Open Access

November 7, 2022

Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis

  • Wei Shen,
  • Michael S. Middleton,
  • Guilherme M. Cunha,
  • ...
  • Jane Zhou,
  • Claude B. Sirlin,
  • Joel E. Lavine
Published online: November 07, 2022

Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis

  • Xiaofeng Zhang,
  • Jiankang Song,
  • Yuanjian Zhang,
  • ...
  • Jinlin Hou,
  • Haiyu Wang,
  • Jinjun Chen
Published online: November 07, 2022
Open Access

November 6, 2022

Cases of severe acute liver injury following inactivated SARS-CoV-2 vaccination

  • Anand V. Kulkarni,
  • Margarita Anders,
  • Leyla Nazal,
  • Ezequiel Ridruejo,
  • Cumali Efe
Published online: November 06, 2022

November 5, 2022

Attitudes toward liver transplantation for ACLF-3 patients determine equity of access

  • Thierry Artzner,
  • Luca S. Belli,
  • François Faitot,
  • Rajiv Jalan
Published online: November 05, 2022

November 2, 2022

Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH

  • Vlad Ratziu,
  • Stephen A. Harrison,
  • Veronique Loustaud-Ratti,
  • ...
  • Arun Sanyal,
  • Jacky Vonderscher,
  • Pietro Scalfaro
Published online: November 02, 2022
Open Access

Reply to: “Ammonia and prognosis of cirrhosis: A new perspective for identifying high risk patients”

  • Thomas H. Tranah,
  • María-Pilar Ballester,
  • Juan Antonio Carbonell-Asins,
  • Rajiv Jalan,
  • Debbie L. Shawcross
Published online: November 02, 2022

November 1, 2022

Reply to: “Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?”

  • Thomas H. Tranah,
  • María-Pilar Ballester,
  • Juan Antonio Carbonell-Asins,
  • Rajiv Jalan,
  • Debbie L. Shawcross
Published online: November 01, 2022

October 31, 2022

Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma

  • Carlo Sposito,
  • Francesca Ratti,
  • Alessandro Cucchetti,
  • ...
  • Felice Giuliante,
  • Luca Aldrighetti,
  • Vincenzo Mazzaferro
Published online: October 31, 2022

October 30, 2022

October 28, 2022

Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression

  • Edward J. Gane,
  • P. Rod Dunbar,
  • Anna E. Brooks,
  • ...
  • Anuj Gaggar,
  • Shyamasundaran Kottilil,
  • Lydia Tang
Published online: October 28, 2022

October 27, 2022

MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells

  • Lea Duwe,
  • Patricia Munoz-Garrido,
  • Monika Lewinska,
  • ...
  • Jill Koshiol,
  • Colm J. O'Rourke,
  • Jesper B. Andersen
Published online: October 27, 2022
Open Access

October 26, 2022

Detection of unreported alcohol consumption in fatty liver disease

  • Katharina Staufer,
  • Brian Mangal,
  • Michael Trauner
Published online: October 26, 2022

Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosis

  • Beiling Li,
  • Changze Hong,
  • Zhiping Fan,
  • ...
  • Qifa Liu,
  • Rajiv Jalan,
  • Jinjun Chen
Published online: October 26, 2022
Open Access

Treatment of HCC with Claudin-1 specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment

  • Natascha Roehlen,
  • Marion Muller,
  • Zeina Nehme,
  • ...
  • Catherine Schuster,
  • Laurent Mailly,
  • Thomas F. Baumert
Published online: October 26, 2022
Open Access

October 25, 2022

Advertisement